Bruker (NASDAQ:BRKR) Trading 3.6% Higher – Should You Buy?

Bruker Corporation (NASDAQ:BRKR)’s share price rose 3.6% during mid-day trading on Thursday . The company traded as high as $60.82 and last traded at $61.8050. Approximately 70,144 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 2,355,954 shares. The stock had previously closed at $59.67.

Analyst Ratings Changes

BRKR has been the subject of a number of recent analyst reports. UBS Group assumed coverage on shares of Bruker in a report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective for the company. Stifel Nicolaus set a $50.00 target price on Bruker in a research note on Wednesday, August 5th. Guggenheim lifted their target price on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Barclays boosted their price target on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Bruker Stock Up 2.0%

The company has a 50-day moving average of $58.27 and a two-hundred day moving average of $50.44. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company has a market capitalization of $9.27 billion, a PE ratio of -87.04, a P/E/G ratio of 1.87 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same period last year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio is -28.57%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Essential Partners LLC purchased a new stake in shares of Bruker in the first quarter valued at $36,000. Global Retirement Partners LLC purchased a new position in shares of Bruker during the 2nd quarter worth about $38,000. EverSource Wealth Advisors LLC boosted its stake in shares of Bruker by 532.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock worth $54,000 after purchasing an additional 1,263 shares during the period. FNY Investment Advisers LLC bought a new position in Bruker during the 2nd quarter valued at about $60,000. Finally, IFP Advisors Inc raised its position in Bruker by 88.6% in the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock worth $64,000 after purchasing an additional 498 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.